vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

August 16, 2016 7:28 AM EDT

vTv Therapeutics (NASDAQ: VTVT) reported Q2 EPS of ($0.47). Revenue for the quarter came in at $182 thousand, versus $110 thousand reported last year.

Cash, cash equivalents and marketable securities as of June 30, 2016 were $63.8 million, compared to $88.0 million as of December 31, 2015. The Company expects that its cash,... More